IMUX, US4525EP2001

Immunic stock has results scheduled for November 12

Published on 10/17/2026 at 19:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immunic's 52-week low was USD 5.06 on October 16, 2026. Immunic stock costs EUR 6.19 on October 16, 2026, down 1.83 percent on Nasdaq.

Results date and valuation

MarketBeat lists November 12, 2026 for Immunic's next quarterly results.
The stock stood 37.75 percent above its 52-week low on October 16, 2026.
Immunic stock was last at EUR 6.19 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST, while Nasdaq trading ended down 1.83 percent.
Immunic had a USD 95.1 million market capitalization and a negative 1.45 price-to-earnings ratio on October 16, 2026.

IMUX, US4525EP2001, Illustration mit AI erstellt.

Immunic's next quarterly results are scheduled for November 12, 2026, according to MarketBeat. The date gives investors the next fixed checkpoint for a clinical-stage biotechnology company whose lead program is being tested in multiple sclerosis. The last euro quote was EUR 6.19 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST; Nasdaq trading closed at USD 6.97, down 1.83 percent from USD 7.10.

Range remains wide

Immunic traded between USD 5.06 and USD 17.43 over the 52 weeks ending October 16, 2026. The Nasdaq price of USD 6.97 stood 37.75 percent above the low and 59.96 percent below the high, underlining how widely the stock has moved during the period.

The company is developing oral therapies for neurologic and autoimmune diseases, with vidofludimus calcium as its lead development program. Immunic's investor-relations page says top-line data from Phase 3 studies are expected by the end of 2026, while another Phase 3 study in progressive multiple sclerosis is expected to begin later in 2026.

Valuation and next date

Immunic had a market capitalization of USD 95.1 million on October 16, 2026. Its price-to-earnings ratio was negative 1.45, reflecting the company's clinical-development stage rather than an established commercial earnings base. MarketBeat also lists a consensus estimate of negative USD 0.94 earnings per share for the third quarter of 2026.

Comparison with peers

Immunic (Nasdaq, USD): minus 1.83 percent, P/E minus 1.45, market capitalization USD 95.1 million
TG Therapeutics (Nasdaq, USD): minus 3.62 percent, P/E 19.70, market capitalization USD 8.3 billion
Prothena Corporation (Nasdaq, USD): minus 1.76 percent, P/E minus 9.94, market capitalization USD 428.7 million

What the price shows

The comparison places Immunic alongside larger biotechnology companies with different earnings profiles. TG Therapeutics had a positive price-to-earnings ratio, while Prothena and Immunic remained loss-making on that measure. The November reporting date is the next scheduled point at which clinical progress and cash use may receive a fresh update.

The last available euro quote was EUR 6.19 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST. Nasdaq's closing price on the same date was USD 6.97, down 1.83 percent from USD 7.10.

The further course of trading is shown by the continuously updated real-time quote of Immunic stock.